-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Recommendation of "Hold" by Brokerages
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Recommendation of "Hold" by Brokerages
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Rating) have been given a consensus recommendation of "Hold" by the nine research firms that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $3.96.
Several equities analysts have recently weighed in on the stock. Piper Sandler raised their price target on shares of Rigel Pharmaceuticals from $1.00 to $2.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 16th. StockNews.com cut shares of Rigel Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, September 13th. Cantor Fitzgerald cut shares of Rigel Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $6.00 to $1.00 in a research note on Wednesday, June 8th. HC Wainwright raised their target price on shares of Rigel Pharmaceuticals from $7.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, August 18th. Finally, B. Riley decreased their target price on shares of Rigel Pharmaceuticals from $4.00 to $1.25 and set a "neutral" rating for the company in a research note on Thursday, June 9th.
Get Rigel Pharmaceuticals alerts:Rigel Pharmaceuticals Stock Performance
Shares of RIGL stock opened at $1.21 on Thursday. The company has a debt-to-equity ratio of 4.39, a quick ratio of 2.08 and a current ratio of 2.19. The company has a market capitalization of $209.13 million, a P/E ratio of -2.47 and a beta of 1.54. The company's 50 day moving average price is $1.39 and its two-hundred day moving average price is $1.91. Rigel Pharmaceuticals has a 52 week low of $0.64 and a 52 week high of $3.91.
Institutional Investors Weigh In On Rigel Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its stake in Rigel Pharmaceuticals by 209.2% in the second quarter. Goldman Sachs Group Inc. now owns 1,937,924 shares of the biotechnology company's stock valued at $2,190,000 after purchasing an additional 1,311,254 shares in the last quarter. Woodline Partners LP raised its stake in Rigel Pharmaceuticals by 4.6% during the second quarter. Woodline Partners LP now owns 861,305 shares of the biotechnology company's stock worth $973,000 after acquiring an additional 37,641 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Rigel Pharmaceuticals by 102.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 168,302 shares of the biotechnology company's stock worth $190,000 after acquiring an additional 85,200 shares in the last quarter. State Street Corp raised its stake in Rigel Pharmaceuticals by 218.2% during the second quarter. State Street Corp now owns 23,945,568 shares of the biotechnology company's stock worth $27,058,000 after acquiring an additional 16,421,362 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in Rigel Pharmaceuticals by 308.2% during the second quarter. Cubist Systematic Strategies LLC now owns 74,675 shares of the biotechnology company's stock worth $84,000 after acquiring an additional 56,380 shares in the last quarter. Institutional investors and hedge funds own 80.94% of the company's stock.About Rigel Pharmaceuticals
(Get Rating)
Rigel Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.
Read More
- Get a free copy of the StockNews.com research report on Rigel Pharmaceuticals (RIGL)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Rating) have been given a consensus recommendation of "Hold" by the nine research firms that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $3.96.
Marketbeat.com报道，报道该股的九家研究公司已向锐吉尔制药公司（纳斯达克股票代码：RIGL — Get Rating）的股票给出了 “持有” 的共识建议。五位分析师对该股进行了持有评级，一位分析师对该股给予了买入评级。去年发布该股报告的分析师的平均1年目标价格为3.96美元。
Several equities analysts have recently weighed in on the stock. Piper Sandler raised their price target on shares of Rigel Pharmaceuticals from $1.00 to $2.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 16th. StockNews.com cut shares of Rigel Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, September 13th. Cantor Fitzgerald cut shares of Rigel Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $6.00 to $1.00 in a research note on Wednesday, June 8th. HC Wainwright raised their target price on shares of Rigel Pharmaceuticals from $7.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, August 18th. Finally, B. Riley decreased their target price on shares of Rigel Pharmaceuticals from $4.00 to $1.25 and set a "neutral" rating for the company in a research note on Thursday, June 9th.
几位股票分析师最近对该股进行了权衡。派珀·桑德勒在8月16日星期二的一份研究报告中将锐佳制药的目标股价从1.00美元上调至2.00美元，并将该股评级定为 “中性”。StockNews.com在9月13日星期二的一份研究报告中将锐吉尔制药的股票评级从 “买入” 下调至 “持有”。坎托·菲茨杰拉德在6月8日星期三的一份研究报告中将锐佳制药的股票从 “增持” 评级下调至 “中性” 评级，并将该公司的目标价格从6.00美元下调至1.00美元。HC Wainwright在8月18日星期四的一份研究报告中将锐佳制药的目标价格从7.00美元上调至15.00美元，并将该公司评为 “买入”。最后，B. Riley将Rigel Pharmicals股票的目标价格从4.00美元下调至1.25美元，并在6月9日星期四的一份研究报告中为该公司设定了 “中性” 评级。
Rigel Pharmaceuticals Stock Performance
里格尔制药股票表现
Shares of RIGL stock opened at $1.21 on Thursday. The company has a debt-to-equity ratio of 4.39, a quick ratio of 2.08 and a current ratio of 2.19. The company has a market capitalization of $209.13 million, a P/E ratio of -2.47 and a beta of 1.54. The company's 50 day moving average price is $1.39 and its two-hundred day moving average price is $1.91. Rigel Pharmaceuticals has a 52 week low of $0.64 and a 52 week high of $3.91.
周四，RIGL股票开盘价为1.21美元。该公司的债务与权益比率为4.39，速动比率为2.08，流动比率为2.19。该公司的市值为2.0913亿美元，市盈率为-2.47，beta为1.54。该公司的50天移动平均线价格为1.39美元，其两百天移动平均线价格为1.91美元。锐佳制药创下52周低点0.64美元，52周高点3.91美元。
Institutional Investors Weigh In On Rigel Pharmaceuticals
机构投资者对瑞吉尔制药的看法
About Rigel Pharmaceuticals
关于锐佳制药
(Get Rating)
（获取评分）
Rigel Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.
Rigel Pharmicals, Inc. 是一家生物技术公司，发现并开发了用于治疗血液系统疾病、癌症和罕见免疫疾病的小分子药物。该公司提供Tavalisse，一种口服脾酪氨酸激酶抑制剂，用于治疗慢性免疫性血小板减少症的成年患者。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Rigel Pharmaceuticals (RIGL)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 免费获取 StockNews.com 关于锐吉尔制药（RIGL）的研究报告的副本
- 对于塔吉特来说，最糟糕的时期可能已经过去，但是该股票可以安全买入吗？
- 这些液化天然气股票准备好上行反弹了吗？
- 业内人士正在购买的两只有趣的股票
- 在避险市场中，Novavax 仍然是冒险股票
- 3只具有60年股息连续上调的防御性股票
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收《锐吉尔制药日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收锐吉尔制药及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧